Results 271 to 280 of about 231,111 (314)

Active Immunotherapy by B.C.G.

1971
Immunotherapy is a new method of killing malignant cells in the treatment of cancer. It is well known, from the rejection of incompatible grafts, that membrane antigens can excite an immune reaction capable of killing cells carrying these antigens. It is also known that these immune reactions can sometimes fail to kill the cells that have raised the ...
G. Mathe, J. L. Amiel, L. Schwarzenberg, M. Schneider   +3 more
openaire   +1 more source

Active-specific immunotherapy for melanoma.

Journal of Clinical Oncology, 1990
Twenty-five patients with metastatic melanoma were treated with a therapeutic vaccine ("theraccine") consisting of allogeneic melanoma lysates and a novel adjuvant, DETOX (Ribi ImmunoChem Research, Inc, Hamilton, MT). Each patient received 200 antigenic units (20 x 10(6) tumor cell equivalents) subcutaneously on weeks 1, 2, 3, 4, and 6.
M S, Mitchell, W, Harel, R A, Kempf, E, Hu, J, Kan-Mitchell, W D, Boswell, G, Dean, L, Stevenson   +7 more
openaire   +2 more sources

Inflammasome-Activating Nanovaccine for Cancer Immunotherapy

Cancer Research
A range of advanced nanovaccines (NV) combined with immunotherapies has recently emerged for treating malignant tumors and has demonstrated promising tumor-suppressive effects. Nevertheless, their effectiveness is often limited by immunosuppression within the tumor microenvironment.
Wenyao Zhen, Xiaoyuan Chen
openaire   +2 more sources

Active Specific Immunotherapy in Colon Cancer

2005
Colorectal cancer is one of the leading causes of cancer-related mortality. After a series of clinical trials, the adjuvant 5-FU-based chemotherapy has established a definitive role in the management of stage III colon cancer. While the precise role for chemotherapy in stage II disease remains under investigation, less toxic treatment modalities such ...
openaire   +3 more sources

Cancer Local Active Immunotherapy

1976
As the mixture of BCG and irradiated tumour cells had been shown to be more effective than either one or the other administered alone (MATHE, 1968; MATHE et al., 1969), it was tempting, in the case of a perceptible tumour, to inject BCG or another adjuvant into the neoplasia. This was tried on human tumours by MORTON et al.
openaire   +1 more source

Active Immunotherapy for Solid Tumours

1997
Although the concept of treating human cancer with vaccines has been explored for several decades, it is only in the last 10–15 years that a concerted effort has started to be made to prove or disprove the possibility that “therapeutic vaccines” may have more than just anecdotal efficacy against cancer.
A. Maraveyas, A. G. Dalgleish
openaire   +1 more source

Immunotherapy and mast cell activation.

Allergie et immunologie, 1999
Tryptase is the more specific markers for mast cell activation and mediators release and can be used as an index of mast cell activation after challenge. Nasal provocation tests have been done in patients allergic to the pollen of Parietaria (pellitory wall) before and after specific systemic immunotherapy and tryptase release evaluated in nasal lavage
A G, Carlos, M L, Carlos, M A, Santos, E, Pedro, S, Santos, A, Lopes-Pregal   +5 more
openaire   +1 more source

If active immunotherapy doesn't work...

JAMA: The Journal of the American Medical Association, 1979
The honey bee, at least according to one school of entomological thought, shares with the yellow jacket the distinction of being among the most common of the venomous stinging insects. Only the female honey bee stings, usually only on perceiving a threat.
openaire   +1 more source

Integrative oncology: Addressing the global challenges of cancer prevention and treatment

Ca-A Cancer Journal for Clinicians, 2022
Jun J Mao,, Msce, Lorenzo Cohen, Karen M Mustian   +2 more
exaly  

Active Tumor Immunotherapy with BCG

SOUTHERN MEDICAL JOURNAL, 1973
E, Rosenberg, R, Powell
openaire   +2 more sources